ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08945
-0,01%
Bitcoin
66.793,64
-0,43%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Day One Biopharmaceuticals Inc (DAWN)

  7. Day One Biopharmaceuticals Inc (DAWN) News

DAWN

Day One Biopharmaceuticals (DAWN)

Day One Biopharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:DAWN
DatumZeitQuelleÜberschriftSymbolFirma
18/05/202400h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DAWNDay One Biopharmaceuticals Inc
18/05/202400h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DAWNDay One Biopharmaceuticals Inc
17/05/202400h34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DAWNDay One Biopharmaceuticals Inc
17/05/202400h21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DAWNDay One Biopharmaceuticals Inc
15/05/202400h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DAWNDay One Biopharmaceuticals Inc
06/05/202422h35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DAWNDay One Biopharmaceuticals Inc
06/05/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAWNDay One Biopharmaceuticals Inc
07/03/202422h19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAWNDay One Biopharmaceuticals Inc
29/02/202401h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DAWNDay One Biopharmaceuticals Inc
27/02/202422h27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DAWNDay One Biopharmaceuticals Inc
21/02/202400h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DAWNDay One Biopharmaceuticals Inc
21/02/202400h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DAWNDay One Biopharmaceuticals Inc
16/02/202423h51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DAWNDay One Biopharmaceuticals Inc
17/01/202414h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAWNDay One Biopharmaceuticals Inc
10/01/202401h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DAWNDay One Biopharmaceuticals Inc
10/01/202401h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DAWNDay One Biopharmaceuticals Inc
08/01/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAWNDay One Biopharmaceuticals Inc
04/01/202422h06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DAWNDay One Biopharmaceuticals Inc
18/11/202300h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DAWNDay One Biopharmaceuticals Inc
18/11/202300h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DAWNDay One Biopharmaceuticals Inc
17/11/202313h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAWNDay One Biopharmaceuticals Inc
17/11/202300h24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DAWNDay One Biopharmaceuticals Inc
15/11/202322h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAWNDay One Biopharmaceuticals Inc
06/11/202322h48Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DAWNDay One Biopharmaceuticals Inc
06/11/202322h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAWNDay One Biopharmaceuticals Inc
30/10/202315h54Dow Jones NewsDay One Biopharmaceuticals Shares Rally on FDA Priority ReviewNASDAQ:DAWNDay One Biopharmaceuticals Inc
30/10/202313h58Dow Jones NewsDay One Gets FDA Priority Review of Tovorafenib in Pediatric Brain TumorNASDAQ:DAWNDay One Biopharmaceuticals Inc
30/10/202313h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DAWNDay One Biopharmaceuticals Inc
20/10/202322h01Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:DAWNDay One Biopharmaceuticals Inc
14/09/202323h28Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:DAWNDay One Biopharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:DAWN

Kürzlich von Ihnen besucht

BIT
P20RP3
NLBNPIT20RP3 20991231 11...
ASX
DMPKOC
BIT
S29028
Societe Generale Effekten
BIT
P1ZMH8
NLBNPIT1ZMH8 20240621 48
BIT
P20E97
NLBNPIT20E97 20351221 6....
NASDAQ
VLATW
Valor Latitude Acquisition
USOTC
GSEFF
Convivio (PK)
BIT
P1TUX1
NLBNPIT1TUX1 20240621 160
ASX
WGN
Wagners
BIT
P1UG34
NLBNPIT1UG34 20991231 4....
BIT
P1W9G3
NLBNPIT1W9G3 20351221 24...
EU
TSLQT
Leverage Shares -3x Shor...
COIN
WIBUSD
COIN
XCOMUSD
BIT
P1ZMQ9
NLBNPIT1ZMQ9 20241220 1.8
BIT
P1ZQK3
NLBNPIT1ZQK3 20241220 600
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten